Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Company News

AbbVie records $4B impairment on Stemcentrx deal

January 6, 2019 7:43 PM UTC

As multiple companies were announcing new deals on the eve of J.P. Morgan Healthcare Conference, AbbVie Inc. (NYSE:ABBV) found itself acknowledging one of its biggest deals was a flop. The company said Friday it will record a $4 billion impairment charge on its 2016 acquisition of Stemcentrx Inc.

AbbVie paid $5.8 billion up front for Stemcentrx and its cancer compound Rova-T rovalpituzumab tesirine...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Abbvie Inc.